Lykan Bioscience Welcomes Kenneth LeClair as Chief Technology Officer
News provided by
Share this article
Share this article
HOPKINTON, Mass., April 13, 2021 /PRNewswire/ Lykan Bioscience, a contract development and manufacturing services organization and provider of the first true end-to-end solution for the manufacture of cell-based therapies, welcomes Kenneth LeClair as Chief Technology Officer. Ken joins the executive leadership team and will be responsible for leading the company s Manufacturing Science and Technology and Process Development teams.
Ken brings over 40 years of academic and industry experience to the Lykan team. Prior to Lykan, Ken was VP of Technical Development and Manufacturing at TScan Therapeutics and Editas Medicine. Before that, he spent 8 years at Novartis, transitioning biologic candidates from research into clinical development. Ken was also responsible for the early technical diligence and supply chain development for the CAR-T product, Kymr